Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2012

eBioscience Sheds Western Blot Line

  • Rockland Immunochemicals today said it expanded its footprint in Western blotting products by acquiring the TrueBlot® IP/Western blot product line from eBioscience for an undisclosed sum, less than a year after all of eBioscience was bought by Affymetrix for $315 million.

    The deal takes eBioscience out of the global Western blotting market, estimated at $1 billion, as the Affymetrix-owned company refocuses toward its evolving flow cytometry, immunoassay, and immunohistochemistry applications in immunology, oncology, and other therapeutic areas.

    Those areas attracted Affymetrix to eBioscience when it acquired the company in an all-cash deal completed in June and explained as improving Affy’s diagnostics business.

    Rockland said it will market the TrueBlot IP/Western blot product line on its e-commerce website and through its existing global distribution network. TrueBlot reagents are designed for researchers to generate publication-quality data from immunoprecipitation and Western blot experiments.

    "The acquisition of the TrueBlot product line expands Rockland’s Western blot workflow product offerings and will allow our customers to perform protein research in a more efficient and effective manner," Jim Fendrick, Rockland’s president and CEO, said in a statement.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »